| 贝伐珠单抗联合多西他赛治疗Her-2阴性复发转移性乳腺癌的疗效观察 |
| |
| 引用本文： | 黄红艳,江泽飞,王涛,张少华,边莉,曹阳,吴世凯,宋三泰.贝伐珠单抗联合多西他赛治疗Her-2阴性复发转移性乳腺癌的疗效观察[J].中国癌症杂志,2011,21(3). |
| |
| 作者姓名： | 黄红艳 江泽飞 王涛 张少华 边莉 曹阳 吴世凯 宋三泰 |
| |
| 作者单位： | 军事医学科学院附属医院乳腺肿瘤科,北京,100071 |
| |
| 基金项目： | 国家自然科学基金青年项目 |
| |
| 摘 要： | 背景与目的:贝伐珠单抗是首个抗血管生成的分子靶向药物,可以与多种化疗药物联合用于治疗复发转移性乳腺癌.本研究旨在观察贝伐珠单抗联合多西他赛治疗复发转移性乳腺癌的疗效和不良反应.方法:28例Her-2阴性的复发转移性乳腺癌患者均接受贝伐珠单抗联合多西他赛方案治疗,多西他赛75 mg/m2静滴,第1天:同时给予贝伐珠单抗15 mg/kg,第1天;21 d为1个周期.每个周期评价疗效同时记录不良反应.结果:27例患者可评价疗效和不良反应,其中CR 1例,PR 21例,有效率(CR+PR)为81.5%.粒细胞减少及白细胞减少是主要的不良反应,Ⅳ度粒细胞减少发生率为85.2%.研究中观察到高血压3例,静脉血栓1例,分级均为1级.蛋白尿12例,鼻衄15例,均为1～2级.结论:贝伐珠单抗联合多西他赛是治疗Her-2阴性的复发转移性乳腺癌患者的有效方案,其不良反应能够耐受.
|
| 关 键 词： | 贝伐珠单抗 多西他赛 乳腺癌 |
The clinical study of bevacizumab combination with docetaxel in the treatment of metastatic Her-2 negative breast cancer patients |
| |
| HUANG Hong-yan,JIANG Ze-fei,WANG Tao,ZHANG Shao-hua,BIAN Li,CAO Yang,WU Shi-kai,SONG San-tai.The clinical study of bevacizumab combination with docetaxel in the treatment of metastatic Her-2 negative breast cancer patients[J].China Oncology,2011,21(3). |
| |
| Authors: | HUANG Hong-yan JIANG Ze-fei WANG Tao ZHANG Shao-hua BIAN Li CAO Yang WU Shi-kai SONG San-tai |
| |
| Affiliation: | HUANG Hong-yan,JIANG Ze-fei,WANG Tao,ZHANG Shao-hua,BIAN Li,CAO Yang,WU Shi-kai,SONG San-tai(Department of Breast Cancer,Affiliated Hospital,Academy of Military Sicence,Beijing 100071,China) |
| |
| Abstract: | Background and purpose:Bevacizumab has emerged as the first antiangiogenic target drug that can be combined with different cytotoxicity agents to treat metastatic breast cancer.This study evaluated the efficacy and toxicity of bevaizumab in combination with docetaxel for patients with Her-2 negtive metastatic breast cancer.Methods:Twenty-eight patients were selected and treated with bevacizumab(15 mg/kg) in combination with docetaxel(75 mg/m2).All patients received docetaxel 75 mg/m2 iv on d 1 and bevacizum... |
| |
| Keywords: | Her-2 |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
|
